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We previously reported high expression of RAD51 and increased homologous recombina-
tion (HR) rates in multiple myeloma (MM) cells, and showed that genomic instability and
disease progression are commensurate with HR levels. Moreover, high RAD51 expression
in vivo is associated with chemoresistance and poor patient survival. Doxorubicin (DOX)
is one of the most widely used drug treatments in MM chemotherapy. DOX is cytotoxic
because it induces DNA double-strand breaks, which can be repaired by RAD51-mediated
HR; activation of this pathway thus contributes to resistance. To investigate the role of
RAD51 in MM drug resistance, we assessed the ability of B02, a small-molecule inhibitor of
RAD51, to enhance DOX sensitivity of MM cells. Combining low-toxicity doses of DOX and
B02 resulted in significant synthetic lethality, observed as increased apoptosis and reduced
viability compared to either agent alone, or to the product of their individual effects. In con-
trast, the combination did not produce significant synergy against normal human CD19+ B
cells from peripheral blood. DOX induced RAD51 at both mRNA and protein levels, while
arresting cells in S and G2. DOX treatment also increased the number of RAD51 foci, a
marker of HR repair, so that the fraction of cells with≥5 foci rose fourfold, whereas γH2AX
foci rose far less, implying that most new breaks are repaired. When B02 treatment pre-
ceded DOX exposure, the induction of RAD51 foci was severely blunted, whereas, γH2AX
foci rose significantly relative to basal levels or either agent alone. In MM cells carrying
a chromosomally integrated reporter of HR repair, DOX increased HR events while B02
inhibition of RAD51 blocked the HR response. These studies demonstrate the crucial role
of RAD51 in protecting MM cells from genotoxic agents such as DOX, and suggest that
specific inhibition of RAD51 may be an effective means to block DNA repair in MM cells
and thus to enhance the efficacy of chemotherapy.
Keywords: multiple myeloma, RAD51, H2AX, recombinase, homologous recombination, chemoresistance,
doxorubicin, B02
INTRODUCTION
Multiple myeloma (MM) is a plasma cell cancer arising from
malignant transformation of post-follicular B cells. The disease
is the second most common hematologic malignancy, accounting
for about 15% of all new cases of such cancers. It is essentially
incurable in the majority of patients, accounting for about 20% of
all deaths from hematologic malignancies (1). A major hallmark
of MM cells is their extensive genomic instability, accompanied by
molecular heterogeneity at many levels (2, 3). Although the mech-
anisms underlying these abnormalities are not well understood,
aberrant DNA repair mechanisms have been implicated. We pre-
viously showed high-level expression of the RAD51 recombinase
and its paralogs in MM cell lines in vitro, and also in primary
bone-marrow aspirates from MM patients. We demonstrated that
Rad51 gene induction in MM cell lines increases homologous
recombination (HR) activity and mediates genomic instability
and disease progression, including development of chemotoler-
ance (4). HR is an essential cellular process, enabling cells to
cope with genotoxic stress by repairing DNA interstrand cross-
links (ICLs), stalled/damaged replication forks, and double-strand
breaks (DSBs) with relatively high fidelity (5, 6). RAD51 polymer-
izes onto single-strand overhangs at resected DNA breaks to form a
nucleofilament, which initiates invasion of homologous duplexes
leading to reciprocal and non-reciprocal DNA strand exchanges
(7). It appears to be the pivotal protein driving the HR process,
since its overexpression elicits aberrant recombination events (8,
9) while its suppression lowers recombination frequency (4). A
growing body of evidence suggests that high expression of RAD51
correlates with an enhanced propensity of tumor cells for inva-
siveness (10), aggressiveness (11), poor prognosis (12–17), and
resistance to DNA damage induced by chemotherapeutic drugs
(17–21) or radiotherapy (22). Recently, high RAD51 expression
was reported to have a negative prognostic value for both event-
free and overall survival of MM patients (23). Targeting RAD51
has thus been proposed as a potential anti-cancer treatment, and
downregulation of RAD51 by siRNA has been shown to selectively
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increase the chemotherapeutic sensitivity of human cancer cells
relative to normal cells (24).
Doxorubicin is one of the most widely used drugs in
chemotherapy regimens for MM. Doxorubicin (DOX) interca-
lates between stacked DNA base pairs, inhibiting topoisomerase
II, and subsequently inducing DNA DSBs (25) preferentially in
replicating cells (26). HR and nucleotide excision repair path-
ways (which are primarily active in replicating cells) are thus
critical for the repair of these lesions (27). Consequently, con-
stitutive upregulation of RAD51 and HR in cancer cells has the
potential to create resistance to DOX or other genotoxic drugs.
Non-homologous end-joining (NHEJ), the other major pathway
for DSB-repair, appears to be disrupted in MM cells. As a result,
MM may be particularly dependent on HR, as has been observed
for repair of radiation-induced DSBs when NHEJ is inhibited
(28). MM-cell reliance on RAD51-dependent HR repair, to survive
genotoxic and/or replicative stresses, could be clinically exploited
for synthetic lethality or to widen the therapeutic-dose window,
by combining DNA damaging agents such as DOX with inhibitors
of HR repair. There are precedents in which agents that indirectly
target the function and/or expression of RAD51 were found to
improve the efficacy of MM radio- and chemotherapy (29, 30).
However, no studies have specifically examined the role played
by RAD51 in MM chemoresistance, particularly to DOX, or the
therapeutic potential of RAD51 small-molecule inhibitors in this
disease.
Huang and co-workers identified B02 as a specific inhibitor
of human RAD51 recombinase (31) and demonstrated that B02
blocks HR repair in human embryonic kidney (HEK) and breast
cancer cells and increases their sensitivity to a wide range of DNA
damaging agents (32, 33). Also, Maes et al. reported that B02
enhances DNA damage and apoptosis induced by decitabine in
MM cells (34). Here, we investigated the involvement of RAD51-
mediated HR repair in MM-cell response to DOX, asking whether
B02 will sensitize MM cells to this treatment. We show that DOX
elicits dose-dependent induction of RAD51 expression at both
mRNA and protein levels, and that treated MM cells arrest in the
S and G2 cell-cycle phases wherein HR predominantly occurs.
Treatment with DOX alone evokes a marked increase in nuclear
RAD51 focus formation, an indicator of RAD51-mediated repair,
while the level of unrepaired DNA damage (indicated by γH2AX
foci) remains relatively constant. Pre-treatment with B02, how-
ever, upsets that balance, blocking formation of DOX-induced
RAD51 foci and elevating measures of DNA damage. Conse-
quently, combined treatment with B02 and DOX results in greater-
than-additive cytotoxicity to MM cells. This study demonstrates
that RAD51 is essential for “normal levels” of MM-cell resistance
to DOX treatment, so that direct inhibition of RAD51 could be an
effective addition to clinical regimens, enhancing the efficacy of
genotoxic chemotherapies.
MATERIALS AND METHODS
CELL CULTURE AND REAGENTS
The human MM cell lines NCI-H929 (H929), RPMI 8226, ARP-1,
and U266 (provided by Dr. Shmuel Yaccoby, Myeloma Institute
for Research and Therapy, University of Arkansas for Medical Sci-
ences) and MM.1S (obtained from the ATCC) were maintained
in RPMI-1640 medium with L-glutamine and NaHCO3 (ATCC)
containing 10% FBS (ATCC), 100 U/mL of penicillin, and
100µg/mL of streptomycin (Sigma-Aldrich). All cultures were
maintained at 37°C, 5% CO2, and 70% relative humidity. MM.1S-
DR.GFP cells (from N. Bahlis, University of Calgary, Canada) were
maintained in the same medium, supplemented with 2µg/mL
puromycin (Sigma-Aldrich). DOX-HCl and B02 (Sigma-Aldrich)
were dissolved in DMSO and diluted in cell culture medium for
cell treatment. Normal human peripheral blood CD19+ B cells
(ZenBio) were cultured in ZenBio Lymphocyte Medium.
CELL PROLIFERATION ASSAY
Proliferation of MM-cell lines was monitored by the WST-1 (Clon-
tech) colorimetric cell-count assay. MM cell lines were seeded in
96-well plates at ~8000 cells/well. The cells were treated with or
without B02 (10µM) for 1 h, followed by treatment with vehicle
(DMSO) or DOX (20–160 nM) for 72 h. WST-1 reagent was added
to the culture medium in each well at a 1:10 ratio, and incubation
continued at 37°C for 4 h. Relative cell number was estimated
from absorbance at 450 nm using a spectrophotometer (Molecu-
lar Devices Corp., CA, USA), and the percentage viability of cells
calculated relative to vehicle treatment (set as 100% viability for
dose-response curves).
To determine the effect of Rad51 siRNA on MM-cell chemosen-
sitivity, MM.1S and H929 cells were transfected with an anti-
Rad51-specific siRNA construct, or a scrambled-sequence control,
as previously described (4), using the Amaxa® Nucleofector® II
(Lonza, Germany) and Nucleofector Kit V (Amaxa VCA-1003)
according to the manufacturer’s protocol. At 24 h after trans-
fection, cells were counted and seeded in 96-well plates (~8000
cells/well) and treated as indicated. Cell viability was then assayed
after 72 h by WST-1 as described above.
For viability assays on normal human peripheral blood B
cells, CD19+ B cells were placed in 96-well plates in lympho-
cyte medium (~8000 cells/well) and treated with DOX±B02
as described above. Cell count was estimated by WST-8 assay
(Sigma CCK-8) at 72 h according to the manufacturer’s protocol,
and viability expressed relative to vehicle treatment (set as 100%
viability).
COLONY FORMATION ASSAY
Cells were treated with B02 (10µM) for 1 h, followed by addi-
tion of vehicle (DMSO) or DOX (80 nM). After 24 h, cells were
washed in fresh culture medium and counted. Cells were then sus-
pended at ~1000 cells/mL in 0.5% Sea-Plaque agarose (Lonza) in
RPMI-1640 medium (maintained as liquid at 41°C), and overlaid
onto a bed of solidified 0.6% agarose in RPMI-1640 medium in
six-well plates. Culture medium (~1 ml per well) was added to
keep cells submerged. Plates were incubated for 14–21 days until
colonies were visible on viewing through an inverted microscope,
and colonies of ≥50 cells were counted. The number of colonies,
divided by that observed for vehicle alone, is the fraction surviving
treatment.
ANALYSES OF CELL-CYCLE PHASES, PHOSPHORYLATED HISTONE H3,
AND APOPTOSIS BY FLOW CYTOMETRY
For cell-cycle distribution, 70% ethanol-fixed cells were stained
with propidium iodide (PI) containing RNase A (FxCycle
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PI/RNase, Invitrogen) and analyzed for DNA content using FACS-
Diva Software (BD Biosciences). For detection of phosphorylated
histone H3 (ser10; pHH3) and DNA content, ethanol-fixed cells
were treated with 0.25% Triton X-100, washed, and incubated with
Alexa Fluor 488-conjugated anti-pHH3 (BioLegend, clone 11D8)
in BioLegend Cell Staining Buffer (5µL per 1× 106 cells), and
stained with PI/RNase A. For apoptosis assays, Annexin V-FITC/PI
apoptosis detection kit (Affymetrix, eBioscience) was used.
QUANTITATIVE RT-PCR
Levels of RAD51 mRNA were determined by quantitative real-
time polymerase chain reaction (qRT-PCR). Total RNA was
extracted from cells after each indicated treatment using Qia-
gen RNAeasy Mini Kit (Qiagen) and cDNA reverse-transcribed
from RNA using SuperScript First Strand cDNA synthesis kit
(Invitrogen). Amplified PCR products were detected using a
SYBR Green PCR Master Mix (Roche). Threshold cycle num-
ber (Tc) for each sample was normalized to Tc for cytoplas-
mic β-actin. Primers used for amplification were Rad51 forward
(F) and reverse (R) primers: 5′-CAATGCAGATGCAGCTTGAA-3′
and 5′-CCTTGGCTTCACTAATTCCCT-3′, respectively; and β-
actin F and R primers: 5′-CATCTTGGCCTCACTGTCCA-3′ and
5′-GGGCCGGACTCATCGTATT-3′, respectively.
WESTERN BLOTTING
After the indicated treatments, cells were lysed at 0°C by mild
sonication (3× 10 s) in RIPA buffer (Santa Cruz Biotech) plus
protease inhibitors (Sigma). Protein concentrations were deter-
mined by BCA assay (Thermo Scientific) and equivalent protein
amounts subjected to SDS-PAGE, transferred to polyvinyl diflu-
oride (PVDF) membranes and probed with mouse monoclonal
antibody to RAD51 (Millipore). Membranes were washed in TBST,
incubated with HRP-conjugated goat anti-mouse IgG (Santa Cruz
Biotechnology), washed again, and signal detected by chemilu-
minescence using ECL detection reagent (Bio-Rad). Antibodies
were removed from the membrane by incubation in a solution
containing 2% (w/v) sodium docecylsulfate, 62.5 mM Tris-HCl
pH6.8, and 0.7% (w/w) β-mercaptoethanol for 15 min at 50°C and
the membrane re-probed with primary antibody to actin (Santa
Cruz Biotechnology) and signal detected as described above. Band
intensities were quantified using Quantity One software (Bio-Rad)
and RAD51 intensity in each lane was expressed relative to the
corresponding actin band and normalized to vehicle treatment.
IMMUNOFLUORESCENCE OF CELLS
Cells were treated with or without B02 (20µM) for 6 h followed
by treatment with vehicle (DMSO) or DOX (160 nM) for a further
6 h. Cells were then washed free of external drugs and incubated in
fresh RPMI-1640 medium for a further 24 h. Cells were harvested,
centrifuged onto glass slides (Cytospin 4, Thermo Scientific), and
fixed in 4% paraformaldehyde in PBS, pH 7.4, for 12 min at 22°C,
followed by three 5-min washes in PBS. Cells were permeabilized
(0.1% Triton X-100 in PBS, 15-min), washed in PBS (3×, 5 min
each), and incubated 1 h at 22°C with blocking buffer (1.5% BSA
in PBS). They were reacted >12 h at 4°C with primary antibodies
[1:1000 goat polyclonal anti-RAD51 IgG (Santa Cruz Biotech.);
or 1:1000 mouse monoclonal anti-γH2AX/ser139, clone JBW301
(Millipore)], washed in PBS (3×, 5 min each), and incubated 1 h at
22°C in the dark, with appropriate secondary antibodies [bovine
anti-goat IgG Alexa Fluor 488 for RAD51, or goat anti-mouse IgG
Alexa Fluor 594 for γH2AX (Jackson ImmunoResearch)]. Cells
were washed 3× in PBS and mounted under coverslips with Pro-
long Antifade plus DAPI. Images were acquired with an LSM 510
Zeiss confocal laser-scanning microscope with a 63× oil objective.
For quantitative analysis,≥100 cells from each group were chosen
at random and nuclei counted manually to determine the per-
centage positive for RAD51 and/orγH2AX (i.e., having≥5 discrete
foci/nucleus). Results were averaged from≥3 biological replicates.
Intensities of foci (integrated densities per nucleus) were measured
using ImageJ software, with subtraction of background peripheral
to each nucleus.
HR ASSAY
MM.1S cells containing a chromosomally integrated HR sub-
strate, a“DR-GFP” reporter (from N. Bahlis, University of Calgary,
Canada) were used for HR assay (29, 35). Transient infection
with an adenovirus expressing I-SceI endonuclease, AdNGUS24i
(from N. Bahlis, University of Calgary, and A. Nepveu, McGill
University, Canada), generates a DSB at an I-SceI site within
a mutant GFP (Sce-GFP) copy in tandem with a 5′- and 3′-
truncated GFP gene (iGFP) (36). HR repair of the DSB, templated
by the iGFP partial-repeat copy, restores a functional GFP gene
whose expression is detectable by flow cytometry. MM.1S cells
stably expressing the integrated DR-GFP were cultured 24 h in
medium±AdNGUS24i viral particles, rinsed, and resuspended in
fresh culture medium±B02 (10µM) or DOX (160 nM) and incu-
bated 24 h. Percent live cells (PI−, i.e., impermeable to PI), and the
fraction of PI− cells that were also GFP+, were measured by flow
cytometry to estimate the frequency of HR repair.
STATISTICAL ANALYSIS
All experiments were carried out with at least three samples
per group, and repeated at least twice. Data are expressed as
mean± SEM. GraphPad Prism software (Prism ver. 6, San Diego,
CA, USA) and Excel were used for statistical analysis. Statistical sig-
nificances observed between groups were calculated by two-tailed
t -tests, or by ANOVA with Tukey’s post hoc test for comparisons
of more than two groups. Two-tailed heteroscedastic t -tests were
used to determine significance of differences in DOX effects on
RAD51 protein levels, since sample size was insufficient to ensure
adherence to a Gaussian distribution, or to estimate variance with
high confidence. Uncorrected p values are presented, to permit
reader discretion in defining a threshold between full Bonfer-
roni correction and the p< 0.05 level denoting nominal statistical
significance.
RESULTS
DISRUPTION OF RAD51 POTENTIATES THE SENSITIVITY OF MM CELL
LINES TO DOXORUBICIN
We first used siRNA to assess whether specific inhibition of
Rad51 will enhance DOX chemosensitivity. Anti-Rad51 siRNA
suppressed Rad51 transcript levels relative to control (scrambled
siRNA) by ~65% in MM.1S cells (A) and ~61% in H929 (B) cells,
assessed by qRT-PCR at 24 h (Figure S1 in Supplementary Mate-
rial). DOX (0–160 nM) was added to cells after 24 h, and cell
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Table 1 | Pre-treatments targeting Rad51 sensitize myeloma cells to
DOX.
Cell line DOX IC50 (nM) Fold
change
DOX IC50 (nM) Fold
change
−B02 +B02 scr-siRNA Rad51 siRNA
MM.1S >160 25.4 ≥6.3 >160 60.5 ≥2.6
H929 125 14.9 8.4 126 40.6 3.1
ARP-1 >160 27.3 ≥5.9 – – –
U266 >160 49.0 ≥3.3 – – –
IC50 values for DOXwere calculated from dose-response curves (viability vs. DOX
concentration,±10µMB02) using GraphPad Prism software.Where DOX did not
reach the IC50, the lower limit for IC50 was taken as the highest dose employed,
160 nM. Fold change is the ratio of IC50 values for DOX, “−B02” divided by
“+B02” or “scr-siRNA” (scrambled-sequence control) divided by “Rad51 siRNA.”
number was monitored 72 h later as a measure of survival and
proliferation. Rad51 siRNA significantly potentiated DOX toxicity
in MM cell lines relative to control siRNA (Figures 1A,B; p< 0.01
for seven of eight comparisons), reducing the calculated IC50 for
DOX by 3.1-fold in H929 cells and by >2.6-fold in MM.1S cells
(Table 1).
We then assessed whether B02, a small-molecule inhibitor of
RAD51 (31), would enhance myeloma cell sensitivity to DOX. We
first determined the cytotoxic dose-response of MM cell lines to
B02, to define suitable doses to subsequently combine with DOX.
At 10µM, B02 was moderately toxic (20–24% killing), which was
nominally significant for all lines tested (p< 0.05, Figures 1C,D
and Figure S2 in Supplementary Material) except U266 (p> 0.05;
Figure S2 in Supplementary Material), which was also the cell line
least sensitized to DOX by B02. We then combined 10-µM B02
with a series of DOX doses of increasing toxicity (20–160 nM)
to seek enhanced lethality in four MM-cell lines as assessed by
cell viability, apoptosis, and clonogenic potential. As shown in
Figures 1C,D and Figure S2 in Supplementary Material, this DOX
dose range only exceeded 50% toxicity in H929 cells. Combina-
tions of DOX and B02, however, surpassed 50% toxicity in all cell
lines, reducing the DOX IC50 by 8.4-fold in H929 and at least 6.3-,
5.9-, and 3.9-fold in MM.1S, ARP-1, and U266 cells, respectively
(Table 1).
To evaluate whether the above data for MM cells indicate signif-
icant synergy (synthetic lethality) between RAD51-inhibition and
DOX, we compared cell survival of dual-treatment combinations
to the product of their individual surviving fractions when given
singly, which is the expected effect of combining two drugs that act
independently. Because Rad51 siRNA alone scarcely affected cell-
counts in either MM line, relative to cells exposed to control siRNA,
the significant decreases in cell survival when this siRNA was com-
bined with DOX are also significantly synergistic, with p< 0.01 to
p< 0.001 (as indicated by “+” symbols in Figures 1A,B). When
10-µM B02 was used to inhibit RAD51, cell number was reduced
~25% in each cell line without DOX addition (Figures 1C,D;
Figures S1C,D in Supplementary Material), probably reflecting
the dependence of MM cells on RAD51 (for HR repair of routine
DNA damage), which is strongly inhibited by B02. DOX toxicity
was further elevated by B02 inclusion, achieving significant syn-
ergy at 2–4 DOX doses for each MM cell line – i.e., a reduction
in cell number beyond that predicted from their individual effects
if they were independent (p< 0.05 to <0.01, indicated by “+”
and “++” symbols in Figures 1C,D; Figure S1 in Supplementary
Material).
We next assessed the impact of DOX±B02 treatments on the
viability of normal CD19+ B cells from human peripheral blood.
As shown in Figure 1G, B02, or DOX alone at the maximum
concentrations used did not severely reduce viability of normal
CD19+ B cells relative to control treatment (89% for 10µM B02,
and 75% for 160 nM DOX). Moreover, DOX failed to reach the
IC50 either alone or in combination with B02. B02 only slightly
enhanced DOX toxicity at its highest dose, producing a nominally
significant decrease in viability for both drugs together relative to
DOX alone (p< 0.05; Figure 1G). These data imply that B02 sen-
sitizes normal myeloid cells to DOX far less than it affects myeloma
cells, consistent with increased MM dependence on RAD51.
We selected a sub-IC50 dose of DOX (80 nM) to test the effect
of its combination with 10-µM B02 in assays of colony forma-
tion and apoptosis for MM.1S and H929 cell lines. Clonogenic
survival of MM.1S cells fell 67% with combined exposure to
DOX+B02, rather more than predicted from the 36% decline
for DOX and 21% for B02 alone [in terms of viable fractions,
0.33< (0.64× 0.79)= 0.51, p< 0.03], Figure 1E. Similarly, H929
cells formed 66% fewer colonies with the drug combination, a
larger effect than expected from the 39% decrease for DOX alone
and 25% for B02 alone [0.34< (0.61× 0.75)= 0.46, p< 0.04],
Figure 1F. Apoptosis assays (Figure 2), like the two measures of
cell survival, provide compelling evidence of synergistic killing
for the H929 cell line, in which the apoptotic fraction was high,
although not in MM.1S with less than half as much apopto-
sis (Figures 2C,D). In H929 cells, the combination of 10µM
B02 with 80 nM DOX added 66% apoptosis over DMSO vehi-
cle, well above the effect predicted from 12% elicited by B02 alone
and 36% by DOX alone [0.34< (0.88× 0.64)= 0.56, p≈ 0.0003
for synergy; Figure 2C]. In MM.1S cells, the B02+DOX com-
bination contributed 26% apoptosis over the level with DMSO
alone, significantly greater than 8.4% for B02 or 14.6% for DOX
alone (p≤ 0.05, Figure 2D) but roughly equal to the product
of their individual effects [0.74≈ (0.92× 0.85)= 0.78, not sig-
nificant]. With that one exception, all evidence indicates that
B02 potentiates the toxicity of DOX for all tested MM cell
lines, as indicated by diverse end-points, implying true syn-
ergy between these drugs, i.e., a “greater-than-additive” cytotoxic
effect.
DOXORUBICIN INDUCES INCREASED EXPRESSION OF Rad51 mRNA
AND PROTEIN, AND CAUSES MYELOMA CELLS TO ARREST IN S AND G2
Homologous recombination occurs predominantly in the S and
G2 phases of the cell cycle (37), coinciding with the peak in RAD51
expression (38). RAD51 upregulation can stimulate HR and also
may protect against apoptosis (39). In order to assess whether
RAD51 itself responds to DOX treatment (or the double-strand
DNA breaks it causes), we looked for DOX-induced changes in its
transcript- and protein-level expression, or in the cell-cycle dis-
tribution, which in turn may alter RAD51 abundance. MM.1S
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FIGURE 1 | Rad51 inhibitors potentiate doxorubicin (DOX) toxicity in
myeloma cells but not in normal B cells. (A,B) Interaction of DOX with
anti-Rad51 siRNA for toxicity to myeloma cells in mass culture. Cell lines
MM.1S (A) and H929 (B) were treated with DOX at 0–160 nM, 24 h after
transfection with plasmid expressing either a Rad51-specific siRNA (4) or a
scrambled control siRNA. After a further 72 h, cell survival and proliferation
were estimated by the WST-1 viable-cell assay (Clontech). (C,D) Interaction
of DOX with B02, a small-molecule inhibitor of RAD51, for toxicity to
myeloma cells in mass culture. Cell lines MM.1S (C) and H929 (D) were
treated with DOX at 0–160 nM, ±B02 at 10µM; viable-cell number was
assessed by WST-1 assay after 72 h. (E,F) Effect of DOX±B02 on colony
formation at low density. MM cell lines MM.1S (E) and H929 (F) were
treated with vehicle, DOX (80 nM), B02 (10µM), or both. Clonogenic survival
was assessed in soft agar as described in “Materials and Methods” section.
Mean±SEM is shown for each treatment group, normalized to untreated
cells and combined from three independent experiments. (G) Viability of
normal CD19+ B cells from human peripheral blood was assessed by WST-8
assay (Sigma CCK-8). For comparisons of treatment groups connected by
brackets, *, **, ***, and **** indicate p<0.05, 0.01, 0.001, and 0.0001,
respectively, by heteroscedastic 2-tailed t -tests. Significance of synthetic
lethality was also tested, by comparing the percentage viability for the
combination (B02+DOX), to the percentage viability predicted by
multiplying the surviving fractions after each treatment alone. The
coefficient of variation (CoV) for each product of two treatment survivals is
the geometric mean of the two individual CoVs. The predicted mean and SD
were contrasted to the actual combined-treatment values by a one-tailed
heteroscedastic t test; +, ++, and +++ indicate synergy p values of
<0.05, <0.01, and <0.001, respectively.
cells were exposed to 250 or 500 nM DOX for 6, 12, or 24 h,
before harvesting the cells for analysis. Total RNA was extracted
for qRT-PCR quantitation of transcripts, and total protein was
prepared for western blotting; the remaining cells were analyzed
by fluorescence-activated cell sorting to determine their distribu-
tion across the cell cycle. RAD51 expression as mRNA (Figure 3A)
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FIGURE 2 |The RAD51 inhibitor B02 potentiates doxorubicin-induced
apoptosis in MM cells. Myeloma cell lines H929 (A,C) and MM.1S
(B,D) were treated 72 h with vehicle (DMSO), B02 (10µM), DOX (80 nM),
or B02 plus DOX. (A,B)The percent of cells undergoing apoptosis was
assessed by dual staining with propidium iodide (y axis in each panel) and
FITC-tagged antibody to Annexin V (x axis in each panel). Apoptotic cells
are defined by Annexin V content only, and thus are quantitated as the
sum of the two right quadrants in each FACS panel. Scatter plots are
representative of triplicate samples in each of two independent
experiments, comprising 10,000 cells per run scored by flow cytometry.
All six replicates of each condition produced similar results.
(C,D) Combined data are summarized as the mean±SEM of six data
points from two independent experiments (each with n=3). *,**Pairs of
treatment vs. control groups, connected by brackets, differed significantly
(*p<0.05; **p< 0.01). +++, Synthetic lethality was significant
(p<0.0003), based on a one-tailed heteroscedastic t test comparing the
surviving (non-apoptotic) fraction for B02+DOX combined, vs. the product
of the individual surviving fractions after exposure to either agent alone
(each corrected for the “background” or uninduced level of apoptosis in
cells exposed only to DMSO).
and as protein (Figures 3B,C) show consistent induction by
DOX treatment, relative to untreated cells. Rad51 transcripts were
dependent on both dose and time of DOX exposure, reaching
about sixfold elevation by 12 h at 500 nM, and by 24 h of exposure
to 250 nM DOX (Figure 3A). The protein level roughly doubled
24 h post-treatment for the higher DOX dose (Figures 3B,C).
Cell-cycle analysis (Figure 3D) indicates that DOX-treated cells
accumulate largely in the S and G2 phases of the cell cycle, whether
RAD51 inhibitor was added or not – shifting the total percent-
age of cells in S and G2 from 54 to 96% for DOX alone and
from 57 to 89% for DOX+B02. Since cells in G2 and M phase
have the same DNA content and cannot be distinguished by PI
staining, we used phosphorylation of histone H3 (on ser10) as a
marker for mitotic cells, to partition cells in G2/M into G2 and M
phases (40). This revealed that cells exposed to DOX were mainly
arrested in the G2 phase with <0.1% in M (Figure 3E), consis-
tent with previous studies showing that DOX prevents human
lymphoblasts from traversing G2 (41). In breast cancer and also
soft-tissue osteosarcoma cell lines, DOX arrests cells in S and G2,
and induces RAD51 expression causing resistance to the drug (19,
20, 42). Pre-treatment with B02 had no significant effect on cell-
cycle distribution after DOX exposure, although when added alone
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FIGURE 3 | Doxorubicin effects on MM.1S cells: induction of Rad51
mRNA and protein, and cell-cycle arrest in S and G2. Incubation of MM.1S
cells with 250 or 500 nM DOX for the indicated periods of time leads to
(A) increased Rad51 mRNA levels as assayed by qRT-PCR; (B,C) a dose-
dependent increase in RAD51 protein level, as shown in western blots; and
(D,E) cell-cycle arrest, chiefly in G2. (A) Data from three independent
experiments combined, shown as means±SEM. Significance of differences
between either DOX group vs. DMSO controls (black bars, set to a value of
1), by two-tailed t test: *p< 0.05; **p<0.01; ***p<0.001; ****p<0.0001.
(B) A representative western blot probed with primary antibodies to RAD51
and β-actin. (C) Summary of three independent experiments, combined as
mean±SEM (*p<0.05 or **p<0.01 relative to vehicle treatment alone).
(D) Shift in cell-cycle distribution, indicating arrest in S and G2 phases,
determined by FACS analysis of relative DNA content per cell (based on
fluorescence of DNA with intercalated propidium iodide, in permeabilized
cells). Mean values±SEM are shown for triplicate treatments per experiment
for 2–3 biological replicates (total n=6 or 9). Unadjusted significance of
differences, relative to the same cell-cycle phase of cells exposed only to
DMSO: *p< 0.05; **p<0.01; ***p<0.001; ****p<0.0001. (E) Cells
treated with DOX or vehicle were stained with propidium iodide and Alexa
Fluor 488-conjugated antibody to phosphorylated (ser10) histone H3, to
determine the fraction of G2/M-arrested cells that are in mitosis (M).
it induced a significant increase in G1 arrest (43–59%; p< 0.0001)
at the expense of G2. We showed previously that RAD51 tran-
scripts and protein are elevated in MM cells compared to normal
plasma cells, in the absence of any drug exposure (4). In the cur-
rent study, we find that RAD51 is further upregulated following
chemotherapy with DOX. Based on these observations, in the con-
text of prior evidence that HR repair occurs predominantly in
the S and G2 phases (37), and that RAD51 overexpression has
anti-apoptotic effects (43), we infer that RAD51 could directly
contribute to DOX resistance in MM cells.
B02 BLOCKS THE DOXORUBICIN-INDUCED INCREASE IN RAD51 FOCI,
AND INCREASES THE BURDEN OF UNREPAIRED DNA DAMAGE
Soon after a DSB is formed, histone H2AX (a variant of H2A)
in the region of the break becomes phosphorylated on serine
139. The resulting “γH2AX” sites facilitate recruitment of repair
components and chromatin-modulating factors to the DSB vicin-
ity, and consequently nuclear foci that bind antibody to γH2AX
are widely used as DSB markers (43). RAD51 foci, in contrast,
mark sites where thousands of RAD51 monomers, detectable by
immunostaining, have bound single-stranded DNA overhangs at
DSBs (32); they thus indicate sites of HR repair for DSBs. The two
signals largely colocalize in untreated MM.1S cells with moderate
levels of DNA damage (DMSO images, Figure 4A).
Exposure of these cells to DOX (160 nM) tripled the fraction of
RAD51 focus-positive nuclei relative to vehicle alone (p< 0.0001;
Figure 4B), while the total signal per nucleus rose more than 10-
fold (p< 0.0001; Figure 4C). Exposure of cells to 20µM B02
had no significant effect on RAD51 foci (Figures 4B,C). How-
ever, when many new DSBs were induced by DOX treatment, cells
also exposed to B02 could not respond via HR repair, so the num-
ber and intensity of RAD51 foci fell well below that of γH2AX
foci, to levels not differing significantly from the DMSO control
(Figures 4A–C) but much lower than DOX alone (p< 0.0001).
Low levels of RAD51 foci are associated with a favorable clinical
response to chemotherapy (44). γH2AX foci were only slightly
increased by DOX treatment alone (p> 0.05), whereas the combi-
nation of DOX and B02 evoked marked and significant increases in
the fraction and intensity of γH2AX-positive nuclei (p< 0.0001;
Figures 4B,C), indicating a high steady-state level of unrepaired
DSBs induced by DOX.
B02 DISRUPTS HR-MEDIATED REPAIR OF DSBs IN MM CELLS
We previously showed high expression of RAD51 and its paralogs,
and elevated HR rates, in both MM-cell lines and in primary
bone-marrow aspirates from MM patients; the MM.1S cell line
in particular overexpressed RAD51 and had consistently robust
HR activity (4). We thus chose this cell line to test whether
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FIGURE 4 | B02 inhibits DOX-induced formation of RAD51 foci,
increases persistence of γH2AX foci, and inhibits HR repair of
I-SceI-induced chromosomal DSBs in MM cells. (A–C) MM.1S cells,
exposed 24 h to DMSO, B02 (20µM), DOX (160 nM), or B02+DOX, were
examined by immunofluorescence to identify foci, and DAPI staining to
define nuclei. (A) Representative images of RAD51 and γH2AX foci in cells
exposed to chemicals indicated at left. (B) Mean percent of cells with ≥5
RAD51 or γH2AX foci, ±SEM, after the exposures indicated; data were
combined from three experiments. ****p<0.0001 for the effect of each
drug treatment, relative to DMSO (vehicle) alone. (C) Mean fluorescence
(integrated pixel intensity per nucleus) ±SEM, of RAD51 and γH2AX foci
after the drug exposures indicated. ****p<0.0001, as in (B). (D–F) B02
inhibits HR repair of I-SceI-induced chromosomal DSBs in MM cells.
(D) Scheme of HR at a cleaved I-SceI site within the integrated DR-GPF
locus. Chromosomal DSBs are first introduced at the single insertion site
of the DR-GFP reporter, via cleavage at a unique I-SceI site by site-specific
endonuclease introduced by adenovirus infection. HR repair of these DSBs
creates intact GFP genes, detected by flow cytometry. (E) Examples of
flow-cytometric analysis of MM.1S-DR-GFP cells, wherein GFP
fluorescence (x axis signal) beyond the control boundary (segmented line)
indicates HR repair. Background signal (1.8% of cells), defined in cells
without I-SceI introduction, rose to ~24% after I-SceI expression. Lower
panels show results for I-SceI-exposed cells +B02 (~5% GFP+) or +DOX
(~93% GFP+). (F) Summary of combined data from runs such as those
illustrated in (E), for cells without I-SceI infection (mock), cells treated with
vehicle (DMSO), 20-µM B02, or 160-nM DOX for 24 h after transient
infection with I-SceI expression adenovirus (AdNUGS24i). HR data
combined from three experiments are presented as means±SEM.
Statistical significance between groups (each n=3) by two-tailed t -tests:
****p<0.0001.
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B02 can inhibit formation of RAD51 foci, and thus decrease HR
repair. MM.1S cells bearing a chromosomally integrated DR-GFP
reporter construct allowed us to measure HR repair in the same
cell line (29, 35). This reporter construct contains a GFP gene
(sceGFP) interrupted by an I-SceI cleavage site, and a truncated
GFP gene (iGFP) just downstream of sceGFP in the same orienta-
tion [Figure 4D and Ref. (35)]. To measure HR, cells were infected
with an adenovirus expressing endonuclease I-SceI (AdNGUS24i)
(36) to generate site-specific DSBs uniquely within the reporter
substrate (since I-SceI sites do not occur elsewhere in the human
genome). DSB-repair via HR, using the downstream truncated
iGFP gene sequence as its template, restores a functional GFP
gene – expression of which is detected by flow cytometry.
We assessed HR rates in MM.1S reporter cells treated with
B02 or DOX. Cells treated with only vehicle (DMSO) were ~24%
GFP+, close to the level reported previously for these cells without
drug treatment (29). GFP+ cells (indicating HR events) increased
~4-fold in DOX-treated cells, relative to vehicle alone (p< 0.0001,
Figures 4E,F). This may actually represent a>4-fold improvement
in HR efficacy, since the fraction of cells repairing the cleaved I-
SceI site cannot exceed 100%. In contrast, GFP+ cells fell>6-fold
after B02 treatment (from 24 to 4%; p< 0.0001, Figure 4E). These
data (Figure 4) indicate that DOX treatment further increases the
already high levels of RAD51 and HR in MM cells, whereas B02
inhibits HR at least sixfold.
DISCUSSION
Targeting DNA repair proteins has been proposed as a means to
selectively sensitize cancer cells to radio- and chemotherapy (45);
however, selection of the appropriate target is essential to achieving
this goal. We previously reported that RAD51 expression and HR
activity are quite generally elevated in MM-cell lines and in pri-
mary bone-marrow aspirates from MM patients, and that RAD51
hyperactivity mediates genomic instability and disease progression
(4). Others have shown that RAD51 expression in MM patients’
plasma cells correlates inversely with survival (23). NHEJ, the alter-
native pathway for DSB-repair, appears to be impaired in MM cells
(28). These observations imply that MM cells depend on RAD51-
dependent HR repair of DSBs, which becomes essential for their
survival of DSB-inducing chemotherapies. RAD51 is thus a wor-
thy therapeutic target for inclusion in chemotherapy cocktails to
treat myeloma. Although DOX has been widely used for clinical
therapy of MM, alone and in combination with other drugs, the
ability of drugs targeting HR to boost cytotoxicity at lower doses
of DOX has the potential to improve its anti-cancer efficacy while
minimizing undesirable side-effects.
In this study, we have demonstrated potentiation of apoptosis,
marked reduction of viability, and decreased clonogenic survival
of myeloma cells following exposure to relatively low doses of DOX
together with a RAD51 inhibitor, B02. While off-target effects
of B02 (unrelated to RAD51) are possible, they appear unlikely
in view of the similar effect on DOX toxicity to MM cells, of
siRNA very specifically targetingRad51. It is especially noteworthy
that these synergistic effects of DOX and B02 chemotherapy were
substantially greater in MM cells than in peripheral B cells, thus
enhancing the therapeutic window for treatment. This preferen-
tial toxicity of the DOX+B02 combination for MM cells supports
our hypothesis that myeloma cells may be especially dependent
on RAD51-mediated HR for survival. In previous studies, agents
that indirectly inhibit the expression and/or function of RAD51
were shown to radiosensitize MM cells (30). However, the present
study is the first to indicate direct involvement of RAD51 in the
chemoresponsiveness of MM cells, in particular to DOX. The clin-
ical use of DOX is limited by dose-dependent cardiotoxicity, which
also appears to be mediated by DSBs (46). Combining relatively
low doses of DOX with DNA repair inhibitors such as B02 may
help mitigate such adverse side-effects.
We showed that DOX treatment induces RAD51 expression and
foci, and arrests cells in S and G2, cell-cycle phases wherein HR pri-
marily occurs. RAD51 overexpression and its induction following
DOX treatment were previously found to contribute to resistance
arising in human soft-tissue sarcoma cells (19). Cell-cycle distribu-
tion is an important factor in DOX toxicity, since the drug appears
to induce DNA damage (47) and apoptosis (48) chiefly in G2.
However, G2 arrest and induction of RAD51 may be protective
mechanisms, allowing time for HR repair of the DOX-induced
lesions and avoidance of apoptosis (49). Interestingly, we found
that addition of B02 to DOX treatment does not significantly alter
the extent of G2 arrest or the cell-cycle distribution seen with DOX
alone.
We found that DOX induces HR repair, whereas B02 suppresses
it without reducing RAD51 foci unless cells were also treated with
DOX (Figure 4). In the presence of DOX, B02 blocks the DOX-
induced increase in RAD51 foci, although the level of unrepaired
DSB sites (γH2AX foci) nearly doubles. These data suggest that
MM cells have sufficient HR repair capacity to cope with the DSBs
induced by 160-nM DOX, but B02 inhibition of RAD51 blocks that
repair process and thus exacerbates DNA damage. NHEJ, an alter-
native DSB-repair pathway, is deficient in myeloma cells; however,
NHEJ inhibition in other cell types redirects DSB-repair to HR
(28). We have thus confirmed an outcome that was predictable
from the above studies: that MM cells should have no effective
means of DSB-repair following abrogation of HR (via direct inhi-
bition of RAD51), leading to their more effective killing by drugs
that generate DSBs.
Induction of RAD51 after DOX treatment may further increase
genomic instability in MM cells due to RAD51-mediated recombi-
nation (9) but this effect could be mitigated by co-treatment with
RAD51 inhibitors such as B02. RAD51 is essential in proliferating
cells, so that its disruption might also be lethal to normal cells.
However, Rad51 is overexpressed in cancer cells relative to nor-
mal cells (50, 51) and its selective inhibition by RNA interference
increases sensitivity to chemotherapeutic killing of human cancer
cells relative to normal cells, both in vitro and in vivo (24). In the
present study, we have demonstrated that a RAD51 small-molecule
inhibitor, B02, selectively enhanced DOX killing of MM cells. Thus
combination therapies incorporating RAD51 inhibitors along with
genotoxic agents such as DOX may offer potential mechanisms to
increase chemotherapeutic efficacy.
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